ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of "Hold" From Brokerages
ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of "Hold" From Brokerages
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) has earned a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $5.80.
據Marketbeat Ratings報道，ProQR治療公司(納斯達克代碼：PRQR-GET Rating)已獲得目前跟蹤該股的9位分析師的共識評級為“持有”。五位股票研究分析師對該股的評級為持有建議，三位分析師對該公司發出了買入建議。在去年更新該股覆蓋範圍的經紀商中，12個月目標價的平均水平為5.80美元。
A number of research firms recently commented on PRQR. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price for the company in a research note on Friday, August 12th. Cantor Fitzgerald downgraded ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, August 15th. HC Wainwright decreased their target price on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Finally, Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, August 12th.
一些研究公司最近對PRQR發表了評論。在5月9日星期一的一份研究報告中，StockNews.com將ProQR治療公司的評級從“賣出”上調為“持有”。Raymond James在8月12日(星期五)的一份研究報告中將ProQR治療公司的評級從“市場表現”上調至“表現優於大盤”，併為該公司設定了2.00美元的目標價。Cantor Fitzgerald在8月15日星期一的一份研究報告中將ProQR治療公司的評級從“增持”下調至“中性”。在5月9日星期一的一份研究報告中，HC Wainwright將他們對ProQR治療的目標價格從4.00美元下調至2.00美元。最後，Chardan Capital在8月12日(星期五)的一份報告中將ProQR治療公司的評級從“買入”下調至“中性”。
ProQR Therapeutics Stock Up 2.2 %
ProQR治療公司股票上漲2.2%
NASDAQ:PRQR opened at $0.79 on Thursday. The company has a market capitalization of $56.31 million, a price-to-earnings ratio of -0.79 and a beta of 0.80. ProQR Therapeutics has a one year low of $0.53 and a one year high of $9.09. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 5.93.
納斯達克：週四開盤報0.79美元。該公司市值為5,631萬美元，市盈率為-0.79，貝塔係數為0.80。ProQR治療公司的一年低點為0.53美元，一年高位為9.09美元。該股的50日簡單移動均線切入位為0.81美元，200日簡單移動均線切入位為0.84美元。該公司的負債權益比率為0.43，速動比率為5.93，流動比率為5.93。
Institutional Investors Weigh In On ProQR Therapeutics
機構投資者對ProQR治療公司的看法
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. ProShare Advisors LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ProQR Therapeutics by 23.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 186,663 shares of the biopharmaceutical company's stock valued at $1,495,000 after buying an additional 35,261 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at $660,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ProQR Therapeutics by 82.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock valued at $560,000 after buying an additional 31,614 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock valued at $31,346,000 after buying an additional 481,325 shares in the last quarter. Institutional investors own 31.07% of the company's stock.
幾家對衝基金和其他機構投資者最近增持或減持了PRQR的股份。ProShare Advisors LLC在第四季度購買了ProQR治療公司的新股份，價值約8萬美元。未來資產環球投資有限公司在第四季度增持了ProQR治療公司的股票23.3%。未來資產全球投資有限公司(Mirae Asset Global Investments Co.Ltd.)目前持有這家生物製藥公司186,663股股票，價值1,495,000美元，上個季度又購買了35,261股。Alps Advisors Inc.在第四季度購買了ProQR治療公司新的股票頭寸，價值66萬美元。康納·克拉克和倫恩投資管理有限公司在第四季度增持了82.4%的ProQR治療公司的股票。康納-克拉克-倫恩投資管理有限公司現在持有69,973股這家生物製藥公司的股票，價值560,000美元，上個季度又購買了31,614股。最後，高盛股份有限公司在第四季度增持了ProQR治療公司的股票14.0%。高盛股份有限公司現在持有這家生物製藥公司3913,394股股票，價值31,346,000美元，上個季度又購買了481,325股。機構投資者持有該公司31.07%的股份。
ProQR Therapeutics Company Profile
ProQR治療公司簡介
(Get Rating)
(獲取評級)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物製藥公司，致力於發現和開發基於RNA的治療遺傳疾病的療法。它主要開發正處於II/III期臨牀試驗的sepofarsen，用於治療Leber先天性黑髮10病的照明試驗；以及正在進行II/III期臨牀試驗的ultevursen，用於治療USH2A介導的視網膜色素變性和USHER綜合徵。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- 免費獲取StockNews.com關於ProQR治療(PRQR)的研究報告
- 阿里巴巴-SW和百度集團-SW最終能在退市恐懼中重整旗鼓嗎？
- 世界摔跤娛樂公司準備被出售了嗎？
- 3種可能在你的觀察名單上獲得一席之地的材料類股
- CrowdStrike股價回落，盈利超出預期
- 這些機構會在安巴雷拉入股抄底嗎？
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProQR治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。